434 results on '"Mimura, Naoya"'
Search Results
2. Clinical impact of airflow obstruction after allogeneic hematopoietic stem cell transplantation
3. Detection of clonal plasma cells in POEMS syndrome using multiparameter flow cytometry
4. Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression
5. Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myeloma
6. UTX inactivation in germinal center B cells promotes the development of multiple myeloma with extramedullary disease
7. The pathogenetic significance of exhausted T cells in a mouse model of mature B cell neoplasms
8. Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinoma
9. A high prevalence of myeloid malignancies in progeria with Werner syndrome is associated with p53 insufficiency
10. Correction: UTX inactivation in germinal center B cells promotes the development of multiple myeloma with extramedullary disease
11. Pharmacokinetically guided, once-daily intravenous busulfan in combination with fludarabine for elderly AML/MDS patients as a conditioning regimen for allogeneic stem cell transplantation
12. DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes
13. Acute effects of bolus water intake on post-exercise orthostatic hypotension and cardiovascular hemodynamics
14. Successful second autologous stem-cell transplantation for patients with relapsed and refractory POEMS syndrome
15. The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells
16. EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma
17. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma
18. Genetic and transcriptional landscape of plasma cells in POEMS syndrome
19. Low incidence of thromboembolism in multiple myeloma patients receiving immunomodulatory drugs; a retrospective single-institution analysis
20. p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma
21. Long-term complete remission following tandem autologous stem cell transplantation and consolidative radiotherapy for refractory mediastinal gray-zone lymphoma
22. Long-term efficacy of partial splenic embolization for the treatment of steroid-resistant chronic immune thrombocytopenia
23. Prognostic impact of serum soluble LR11 in newly diagnosed diffuse large B-cell lymphoma: A multicenter prospective analysis
24. Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia
25. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma
26. Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan
27. Risk factors for CAR‐T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan
28. Supplementary Figure 4 from Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma
29. Supplementary Figure 2 from Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma
30. Supplementary Data from Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition
31. Supplementary Figure Legend from Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma
32. Supplementary Table 3 from Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma
33. Supplementary Figure 5 from Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma
34. Supplementary Figure 1 from Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma
35. Supplementary Figures 1 - 10, Tables 1 - 4 from Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition
36. Data from Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition
37. Supplementary Methods from Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition
38. Supplementary Figure Legends from Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition
39. Novel therapeutic strategies for multiple myeloma
40. Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF-β/Smad pathway suppression in hepatic stellate cells
41. Exhausted T Cells Characterized By Upregulation of Specific Transcription Factors Are Increased in a Mouse Model of De Novo Mature B Cell Neoplasms
42. Unraveling unique features of plasma cell clones in POEMS syndrome with single-cell analysis
43. Combined Therapy with Ixazomib, Lenalidomide, and Dexamethasone for Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome
44. Efficacy of myeloablative allogeneic hematopoietic stem cell transplantation in adult patients with MLL-ELL-positive acute myeloid leukemia
45. Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma
46. Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: A multicenter retrospective study in Japan
47. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma
48. High prevalence of myeloid malignancies in progeria with Werner syndrome is associated with p53 insufficiency
49. Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring CTNNB1 Mutation in Early Clinical Experience
50. Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.